CLINICAL_TRIALS
trial_result
· 2009-11-09
Clinical Trial Update: The CLEVER Study - Coreg And Left Ventricular Mass Regression [Phase 3]
Summary
Phase 3 study evaluating carvedilol (Coreg) for regression of left ventricular mass in left ventricular hypertrophy; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Hypertrophy, Left Ventricular | Phase 3 | Status: COMPLETED | Results posted: 2009-11-09